Welcome to episode 37 of The 5-Minute Investor Podcast, where Stockhouse columnists Jonathon Brown and me, Trevor Abes, each deliver a 2.5-minute stock profile related to recent news stories with investment implications. This week, we’re talking about Theralase Technologies and Oncolytics Biotech, a pair of early-stage drug development stocks at the forefront of cancer research.
Here are Jon’s show notes for episode 37:
- A high-risk, high-reward bet on next-generation oncolytic and antiviral therapies.
- Jon’s cancer-fighting stock in Theralase Technologies (TSXV:TLT), a researcher and developer of light, radiation, sound and drug-activated small molecule compounds to destroy various cancers.
- At the time of writing, Theralase stock last traded at C$0.21, giving back 25 per cent year-over-year, while remaining flat since 2020.
Here are Trevor’s show notes:
- Oncolytics Biotech reports updated anal cancer data showing objective response rate more than double the current standard of care.
- Oncolytics Biotech highlights strong efficacy and translational data in metastatic colorectal cancer; will advance regulatory pathway discussions.
- Trevor’s cancer treatment stock is Oncolytics Biotech (NASDAQ:ONCY), a developer of immunotherapies to weaken tumor defense mechanisms.
- At the time of writing, Oncolytics Biotech stock last traded at US$1.04, adding 6.12 per cent year-over-year, while giving back 48.26 per cent since 2020.
Here’s the most recent trio of episodes:
- Episode 34: Quantum computing stocks.
- Episode 35: Glimmering gold stocks.
- Episode 36: Stocks to leverage Carney budget.
Thanks for listening!
The 5-Minute Investor is on Spotify, YouTube, iHeartRadio, Podbean, Stockhouse or wherever finer podcasts are found.
Join the discussion: Find out what investors are saying about cancer stocks and The 5-Minute Investor Podcast on the Theralase Technologies Inc. and Oncolytics Biotech Inc. Bullboards, and make sure to explore the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
For full disclaimer information, please click here.
